One of the microcap pharma stocks engaged in the manufacturing of active pharmaceutical ingredients (APIs) and finished dosage forms, specializing in cephalosporin antibiotics for global markets. The stock hit a 5 percent upper circuit after reporting a 399.36 percent YOY increase in net profit.
Stock Price Movement
With a market capitalization of Rs. 796.80 crores, the shares of Nectar Lifescience Limited’s stock surged by 5 percent, reaching an upper circuit of Rs. 35.53 per share on Saturday, up from its previous closing price of Rs. 33.84 per share.
Q3 FY25 Result Walkthrough
Coming into the quarterly results of Nectar Lifescience Limited, the company’s consolidated revenue from operations increased by 655.12 percent YOY, from Rs. 452.16 crore in Q3 FY24 to Rs. 454.33 crore in Q3 FY25, and grew by 118.80 percent QoQ from Rs. 427.88 crore in Q2 FY25.
Further, the company’s EBIDT has increased by 5.92 percent, from Rs. 42.2 crore in Q3 FY24 to Rs. 44.7 crore in Q3 FY25.
In Q3 FY25, Nectar Lifescience Limited’s consolidated net profit increased by 399.36 percent YOY, reaching Rs. 7.84 crore compared to Rs. 1.57 crore during the same period last year. As compared to Q2 FY25, the net profit has increased by 40.03 percent, from Rs. 5.60 crore.
The basic earnings per share increased by 400 percent and stood at Rs 0.35 as against Rs 0.07 recorded in the same quarter in the previous year 2024.
Manufacturing facilities and global reach
Nectar Lifesciences operates advanced manufacturing facilities in Punjab and Himachal Pradesh, accredited by global regulatory bodies like the US FDA and EU GMP. With over 80 countries served, the company exports its diverse range of high-quality products, reflecting its commitment to meeting global healthcare needs and maintaining standards.
Business operations
The company focuses on API manufacturing, especially cephalosporins, making it a leading global producer. It also develops oral and sterile formulations, offers contract manufacturing services to pharma companies, and produces menthol and mint derivatives.
Written By – Nikhil Naik
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
